Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Core Insights - Boundless Bio has initiated the KOMODO-1 clinical trial for BBI-940, a first-in-class oral Kinesin degrader targeting breast cancer patients with limited treatment options [2][8] - The company reported a cash position of $107.6 million as of December 31, 2025, which is expected to fund operations into the second half of 2028 [9] - The company has ceased enrollment in the POTENTIATE trial to prioritize the BBI-940 program [4] Financial Performance - Research and Development (R&D) expenses for Q4 2025 were $9.8 million, down from $13.3 million in Q4 2024, and total R&D expenses for the full year 2025 were $44.8 million, compared to $55.3 million in 2024 [9][12] - General and Administrative (G&A) expenses for Q4 2025 were $4.2 million, compared to $5.0 million in Q4 2024, while total G&A expenses for the full year 2025 were $18.7 million, slightly up from $18.0 million in 2024 [9][12] - The net loss for Q4 2025 was $12.9 million, down from $16.4 million in Q4 2024, and the total net loss for the full year 2025 was $58.2 million, compared to $65.4 million in 2024 [9][12] Business Highlights - BBI-940 is designed to disrupt extrachromosomal DNA (ecDNA) segregation, targeting chromosomally unstable cancers, and is currently enrolling patients in the KOMODO-1 trial [2][6] - The company aims to deliver initial safety and efficacy proof-of-concept data for BBI-940 within its existing cash runway timeline [8] - Boundless Bio is focused on addressing the unmet needs in patients with oncogene amplified tumors, which represent 14% to 17% of cancer patients [6]